Rezolute shares patient testimonial with favorable results for ersodetug in Phase 2 study

Rezolute, Inc.

Company released a pre-recorded video detailing a patient's experience in the Phase 2 trial of investigational drug ersodetug.
Video notes favorable results for that single patient but cautions they may not be representative of broader trial outcomes.
Ersodetug is not FDA-approved; no safety or efficacy determination has been made by the agency.
Transcript filed as Exhibit 99.1 includes forward-looking statements and risk factors.
No new quantitative clinical data or regulatory milestones disclosed in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.